The American Society of Clinical Oncology (ASCO), in their 16th Annual Report on Progress Against Cancer – Clinical Cancer Advances 2021, highlight
the preventative role of aspirin in reducing cancer risk for people with a hereditary cancer predisposition. The report explains the massively increased cancer risk experienced by those with the hereditary condition Lynch syndrome. This condition puts people at higher risk of multiple different cancers with the life time cancer risk of colorectal cancer estimated to be in the range of 20-80% compared with a 4-5% risk in the background population. The report emphasises how the CAPP 2 study has shown that long-term daily aspirin use can mitigate this risk with a 44% decrease, for carriers of Lynch syndrome, in colorectal cancer rates. It is important to note this benefit takes in excess of five years to develop but then persists for over 20 years.
‘The optimal dosage and treatment duration remain to be determined.’
For further information please see: